OnNovember 7th, during the 5th China International Import Expo, Ping An Health Insurance, Roche, and OrigiMed announced a strategic cooperation to launch an innovative payment service program for Chinese pan-tumor targets, aiming to help Chinese NTRK-positive patients lower their healthcare costs.

On September 22, 2022, Menarini, an Italian biopharmaceutical company, and OrigiMed, a leading Chinese precision medicine company, announced their strategic cooperation to jointly launch an innovative platform for pan-cancer single-cell precision.

Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide.

OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").

OrigiMed announced that the Human NTRK1/2/3 Genomic Alteration Testing Kit has been granted the Special Review Procedure for Innovative Medical Devices by the Center for Medical Device Evaluation of NMPA.